These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2813479)

  • 21. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine.
    Yuan CS; Foss JF; O'Connor M; Osinski J; Roizen MF; Moss J
    Drug Alcohol Depend; 1998 Oct; 52(2):161-5. PubMed ID: 9800145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region.
    Drinovac Vlah V; Filipović B; Bach-Rojecky L; Lacković Z
    Eur J Pain; 2018 Mar; 22(3):583-591. PubMed ID: 29134730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects.
    Yuan CS
    Ann Pharmacother; 2007 Jun; 41(6):984-93. PubMed ID: 17504835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time.
    Yuan CS; Foss JF; O'Connor M; Karrison T; Osinski J; Roizen MF; Moss J
    Clin Pharmacol Ther; 2000 Apr; 67(4):398-404. PubMed ID: 10801249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone.
    Myers RD; Lankford MF
    Neuropsychopharmacology; 1996 Feb; 14(2):139-49. PubMed ID: 8822536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
    Foss JF
    Am J Surg; 2001 Nov; 182(5A Suppl):19S-26S. PubMed ID: 11755893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for a peripheral action of thyrotropin releasing hormone on gastrointestinal transit in mice.
    Bansinath M; Bhargava HN
    Neuropharmacology; 1988 Apr; 27(4):433-7. PubMed ID: 2901674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine.
    Boscan P; Van Hoogmoed LM; Pypendop BH; Farver TB; Snyder JR
    Am J Vet Res; 2006 Jun; 67(6):998-1004. PubMed ID: 16740093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Taste aversion involving central opioid antagonism is potentiated in morphine-dependent rats.
    Mucha RF
    Life Sci; 1989; 45(8):671-8. PubMed ID: 2779356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of morphine and methylnaltrexone on gastrointestinal pain in healthy male participants.
    Brokjaer A; Olesen AE; Christrup LL; Dahan A; Drewes AM
    Neurogastroenterol Motil; 2015 May; 27(5):693-704. PubMed ID: 25810023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats.
    Gilpin NW; Richardson HN; Koob GF
    Alcohol Clin Exp Res; 2008 Sep; 32(9):1535-42. PubMed ID: 18631323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sigma receptor-induced heavy drinking in rats: Modulation by the opioid receptor system.
    Valenza M; Blasio A; DiLeo A; Cottone P; Sabino V
    Pharmacol Biochem Behav; 2020 May; 192():172914. PubMed ID: 32205151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naltrexone and amperozide modify chocolate and saccharin drinking in high alcohol-preferring P rats.
    Biggs TA; Myers RD
    Pharmacol Biochem Behav; 1998 Jun; 60(2):407-13. PubMed ID: 9632223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial.
    Yuan CS; Foss JF; O'Connor M; Toledano A; Roizen MF; Moss J
    Clin Pharmacol Ther; 1996 Apr; 59(4):469-75. PubMed ID: 8612393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of central mu- but not delta- or kappa-opioid receptors in immunomodulation.
    Nelson CJ; Schneider GM; Lysle DT
    Brain Behav Immun; 2000 Sep; 14(3):170-84. PubMed ID: 10970678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limitations on the antagonistic actions of opioid antagonists.
    Young AM; Woods JH
    Fed Proc; 1982 May; 41(7):2333-8. PubMed ID: 7042396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of restraint stress and intra-ventral tegmental area injections of morphine and methyl naltrexone on the discriminative stimulus effects of heroin in the rat.
    Shaham Y; Stewart J
    Pharmacol Biochem Behav; 1995; 51(2-3):491-8. PubMed ID: 7667374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.
    Eastwood EC; Phillips TJ
    Genes Brain Behav; 2014 Feb; 13(2):226-35. PubMed ID: 24152140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between alcohol- and opioid-induced suppression of rat testicular steroidogenesis in vivo.
    Adams ML; Meyer ER; Cicero TJ
    Alcohol Clin Exp Res; 1997 Jun; 21(4):684-90. PubMed ID: 9194925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.
    Gallate JE; Mallet PE; McGregor IS
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):210-6. PubMed ID: 14663553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.